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Elevated Plasma Fibrinogen Rather Than Residual
Platelet Reactivity After Clopidogrel Pre-Treatment
Is Associated With an Increased Ischemic Risk
During Elective Percutaneous Coronary Intervention
Lawrence Ang, MD,* Khalid Bin Thani, MD, MAS,* Manjusha Ilapakurti, MBBS, MPH,*
Michael S. Lee, MD,† Vachaspathi Palakodeti, MD,* Ehtisham Mahmud, MD*
La Jolla and Los Angeles, California
Objectives This study was undertaken to determine the roles of serum fibrinogen and residual platelet reactivity after clopi-
dogrel pre-treatment on ischemic events after elective percutaneous coronary intervention (PCI).
Background Both elevated serum fibrinogen and high platelet reactivity with thienopyridines are associated with ischemic
cardiovascular events. Elevated fibrinogen also contributes to high on-clopidogrel platelet reactivity. It is un-
known whether fibrinogen and residual platelet reactivity are associated with adverse cardiovascular events
through independent or interactive effects.
Methods A total of 189 patients undergoing elective PCI with clopidogrel pre-treatment (75 mg daily for 7 days or a
600-mg bolus 12 h before recruitment) were prospectively enrolled. Baseline fibrinogen and platelet function
using the VerifyNow P2Y12 assay (Accumetrics, San Diego, California) were obtained. Markers of ischemic myo-
cardial injury were measured every 8 h after PCI.
Results Incidence of troponin-defined periprocedural myocardial infarction (PPMI) (troponin I/T 3 upper limit of nor-
mal) was 13.9% and associated with elevated fibrinogen (363.1  131.0 mg/dl vs. 309.1  99.6 mg/dl; p 
0.017), higher age (68.2  10.1 years vs. 63.0  11.8 years; p  0.040), and elevated platelet count. Fibrino-
gen level and age remained independently associated with PPMI following multiple variable and interaction test-
ing. The incidence of creatine kinase-myocardial band (CK-MB)–defined PPMI (CK-MB 3 upper limit of nor-
mal) was 5.8% and associated with elevated fibrinogen (403.4  128.0 mg/dl vs. 313.5  104.6 mg/dl; p 
0.007). Platelet reactivity measurements were not associated with PPMI by either definition. Fibrinogen 345
mg/dl was significantly associated with both CK-MB–defined (p  0.026) and troponin I/T–defined PPMI (p 
0.036). Fibrinogen effects were most prominent in the absence of systemic inflammation (C-reactive protein
0.5 mg/dl).
Conclusions Elevated fibrinogen is independently associated with the risk of ischemic myocardial injury following elective PCI
with clopidogrel pre-treatment regardless of platelet reactivity as measured by the VerifyNow assay. (J Am Coll
Cardiol 2013;61:23–34) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.037Antiplatelet therapy with aspirin and a thienopyridine
reduces major adverse cardiac events (MACE) following
percutaneous coronary intervention (PCI) (1,2). Platelet
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first authors.Manuscript received May 14, 2012; revised manuscript received September 11,
2012, accepted September 25, 2012.function tests, including traditional light transmission
aggregometry (LTA) and contemporary point-of-care
assays, have identified variable patient response to thien-
opyridine agents, particularly clopidogrel (3). Further-
more, in a number of studies, lower platelet inhibition at
a single time point during thienopyridine therapy (also
called “higher on-treatment platelet reactivity”) has been
associated with a higher risk for adverse thrombotic and
ischemic cardiovascular events following PCI (4,5). How-
ever, platelet function testing does not reliably predict
ischemic outcomes and supports the notion that high
residual platelet reactivity is not the only factor contributing
to these events (4).
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Fibrinogen and Ischemic Risk During Elective PCI January 8, 2013:23–34Multiple prior studies have
identified serum fibrinogen as a
risk factor for both short- and
long-term adverse cardiovascular
events (6–15). As an acute phase
reactant involved in the final
common pathway of the coagu-
lation cascade and essential com-
ponent of platelet crosslinking in
thrombus formation, fibrinogen
possesses a clear biological mech-
anism for its adverse cardiovascu-
lar effects (16). A relationship
between serum fibrinogen and
on-treatment platelet reactivity
has also been demonstrated
(6,17), making it unclear
whether these risk factors are
associated with adverse ische-
mic events through indepen-
dent or interactive effects. This
study was undertaken to clarify
the roles of fibrinogen and on-
clopidogrel residual platelet re-
activity on short-term ischemic
cardiac outcomes following
PCI.
Methods
Patient selection. The study protocol was approved by the
Institutional Review Board of the University of California,
San Diego, and written informed consent was obtained
from study participants. Patients with established coronary
artery disease undergoing elective PCI requiring treatment
with clopidogrel were prospectively recruited and enrolled.
Subjects included those undergoing PCI for stable angina or
unstable angina, or elective PCI with objective evidence of
myocardial ischemia. All subjects were required to have
negative biomarkers of ischemic cardiac injury prior to
enrollment. All subjects received either daily clopidogrel 75
mg for a minimum of 7 days or a 600-mg clopidogrel bolus
loading dose at least 12 h before enrollment. Exclusion
criteria included age younger than 18 years, anemia (hemo-
globin 10 g/dl), thrombocytopenia (platelet count
100,000 cells/l), diagnosis of inherited platelet disorders,
erum triglycerides 400 mg/dl, chronic liver disease, in-
ravenous glycoprotein IIb/IIIa inhibitor administration
within previous 30 days), and positive markers of myocar-
ial injury or acute myocardial infarction (within the previ-
us 72 h). Subjects were not excluded for diagnosis of
ystemic inflammatory diseases, such as rheumatoid arthritis
r systemic lupus erythematosus, or renal failure.
easurements. Baseline demographic information and
aboratory data including complete blood count, complete
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
AUC  area under the
curve
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
CRP  C-reactive protein
LTA  light transmittance
aggregometry
MACE  major adverse
cardiac events
OR  odds ratio
PCI  percutaneous
coronary intervention
PI  platelet inhibition
PPMI  periprocedural
myocardial infarction
PRU  P2Y12 reactivity
unit
ROC  receiver-operating
characteristic
ULN  upper limit of
normalipid panel, serum markers of inflammation (C-reactive Srotein [CRP] and fibrinogen), and cardiac markers of
yocardial ischemia (creatine kinase-myocardial band [CK-
B], troponin I and/or troponin T) were obtained in all
ubjects. Standard laboratory tests were performed by the
linical laboratory at the University of California, San Diego
edical Center. Fibrinogen was measured using the Beck-
an Coulter ACL-TOP analyzer (Beckman Coulter Life
ciences, Indianapolis, Indiana) with Instrumentation Lab-
ratory reagent (Instrumentation Laboratory, Lexington,
assachusetts). Cardiac markers of ischemic injury were
easured every 8 h following PCI until hospital discharge
r up to 24 h to assess degree of myocardial injury. Platelet
unction testing was performed using the bedside rapid
latelet function VerifyNow P2Y12 assay (Accumetrics, San
iego, California). VerifyNow P2Y12 assay design has been
reviously described (18). Briefly, the VerifyNow system
tilizes cartridge-based assays and optical turbidometry to
apidly assess platelet function. The P2Y12 assay features
latelet P2Y12 receptor-specific activation using adenosine
iphosphate (ADP) and prostaglandin E1 agonists to acti-
ate platelets following thienopyridine use. On-treatment
latelet reactivity is reported as “result” P2Y12 reactivity
nits (PRU). High-concentration thrombin receptor-
ctivating protein maximally activates platelets to determine
pre-treatment “base” PRU. Platelet inhibition (PI) or
ercent change in platelet reactivity from baseline is calcu-
ated as: (1  [result PRU/base PRU])  100%.
ample collection. Whole blood samples were obtained
rom the radial or femoral artery via the catheter introducer
heath immediately prior to PCI or from a vein in the
ntecubital fossa using standard phlebotomy techniques.
lood was transferred into standard tubes for serologic assays
nd Bio-One Vacuette tubes (Greiner Bio-One North Amer-
ca, Monroe, North Carolina) containing 3.2% sodium citrate
or platelet function testing.
tatistical analysis. The study was conducted using a
ested case-control design. Sensitive troponin I/T–defined
eriprocedural myocardial infarction (PPMI) was used as
he primary study endpoint, and CK-MB–defined PPMI
as used as the secondary study endpoint. Separate analyses
sing both endpoints were planned. Sample size calculation
as performed based on a previous study showing a rela-
ionship between elevated serum fibrinogen at presentation
nd 48-h MACE (acute myocardial infarction and/or car-
iac death) in patients hospitalized for acute coronary
yndrome (7). In order to detect a 51 mg/dl mean difference
n fibrinogen level between cases and controls, an alpha of
.05, and power of 80%, an estimated 25 subjects were
eeded in each group. Enrollment was continued until 25
roponin I/T–defined PPMI events occurred.
Study data were collected and analyzed using SPSS
oftware (version 18.0, SPSS, Chicago, Illinois). Categorical
ariables are reported as percentages, whereas continuous
ariables are reported as mean  SD. Normal distribution
f continuous variables was confirmed using Kolmogorov-
mirnov testing. The primary PPMI endpoint was prospec-
r
c
P
G
a
s
d
l
d
u
i
a
fi
a
c
m
p
a
n
o
t
d
m
m
R
B
(
s
f
(
l
2
o

g
f
t
r
0
t
p
p
T
t
w
s
P
v
y
p
d
P
25JACC Vol. 61, No. 1, 2013 Ang et al.
January 8, 2013:23–34 Fibrinogen and Ischemic Risk During Elective PCItively defined as either troponin I or troponin T level 3
the upper limit of normal (ULN) (troponin I reference
range 0 to 0.5 ng/ml; troponin T reference range 0 to 0.03
ng/ml) (19), whereas the secondary PPMI endpoint was
defined as CK-MB level 3 ULN (CK-MB reference
ange 0 to 4.8 ng/ml) (19). Definitions of high on-
lopidogrel platelet reactivity used in this study included
RU230 (20) and PRU208 (21) based on results of the
RAVITAS (Gauging Responsiveness with A VerifyNow
ssay–Impact on Thrombosis And Safety) trial. Relation-
hips between continuous variables and outcomes were
etermined using independent-samples 2-tailed t-tests. Re-
ationships between categorical variables and outcomes were
etermined using chi-square tests. Variables with significant
nivariate relationships (p  0.05) were entered together
nto a multiple variable logistic regression model for
nalysis of each outcome. Specific testing between serum
brinogen, measures of platelet reactivity (PRU or PI),
nd markers of systemic inflammation (CRP, platelet
ount, white blood cell count) within a multiple variable
odel was prospectively planned to evaluate for interde-
endent effects. Significant variables after multiple vari-
ble testing (p  0.05) were tested for interactions if
ecessary. To determine a cutoff point for serum fibrin-
gen level predicting PPMI, a receiver-operating charac-
eristic (ROC) curve was plotted for each outcome
efinition. The fibrinogen cutoff level producing the
aximum sum of sensitivity and specificity was deter-
ined, and a 2-tailed p value reported.
esults
aseline subject characteristics. A total of 189 subjects
age 63.8  11.6 years, 74.1% male) were enrolled in this
tudy (Table 1). A high prevalence of cardiovascular risk
actors and prior coronary revascularization was observed
PCI 63.0%, coronary artery bypass grafting 18.0%). Base-
ine fibrinogen was 318.7  107.8 mg/dl, whereas only
6.3% of subjects had elevated CRP 0.5 mg/dl. Mean
n-treatment PRU was 211.6  91.5 (45% with PRU
230), and PI was 35.9  24.9%. There was no angio-
raphic evidence of an adverse event in any study subject
ollowing PCI. A ROC curve was plotted to demonstrate
he relationship between PI and high on-clopidogrel platelet
eactivity defined as PRU230 (area under the curve [AUC]:
.950; p  0.001) (Fig. 1). PI level of 30.9% was determined
o produce the greatest sum of sensitivity and specificity in
redicting PRU 230 (86.5% sensitivity, 90.6% specificity;
 0.001).
roponin-defined PPMI. Post-procedural troponin I or
roponin T was obtained in 95.2% of subjects (n  180)
ith troponin I/T–defined PPMI occurring in 13.9% of
ubjects (Table 2). Subjects with troponin I/T–defined
PMI had higher fibrinogen levels (363.1  131.0 mg/dl
s. 309.1 99.6 mg/dl; p 0.017), were older (68.2 10.1
ears vs. 63.0  11.8 years; p  0.040), and had higherlatelet counts (243.6  64.1 cells  103/l vs. 218.4 
55.5 cells  103/l; p  0.041) compared with those
without a troponin I/T–defined PPMI. There was a trend
towards a greater number of stents used per procedure
among the PPMI group (2.08  0.91 vs. 1.68  1.02; p 
0.065), whereas prevalence of elevated CRP 0.5 mg/dl
(24.0% vs. 25.7%; p  0.86), on-treatment PRU (226.0 
81.5 vs. 209.8  92.1; p  0.41), and PI (31.1  20.3% vs.
Baseline Subject Population CharacteristicsTable 1 Baseline Subject Population Characteristics
Clinical characteristics
Age, yrs 63.8 11.6
Male 74.1%
BMI, kg/m2 28.4 5.5
Past PCI 63.0%
Past CABG 18.0%
Past MI 29.7%
Hypertension 90.5%
Hyperlipidemia 89.4%
Diabetes mellitus 46.6%
Family history of CVD 29.9%
Smoking history 16.1%
Current PCI indication
Stable angina 56.1%
Unstable accelerating angina 23.8%
Other symptoms 10.6%
Positive stress test 9.5%
Medications
Aspirin 97.4%
Statin 83.5%
Beta-blocker 74.1%
ACE inhibitor/ARB 61.9%
Nitrates 30.0%
Calcium channel blocker 24.3%
Clopidogrel (75 mg daily 7 days) 84.7%
Percutaneous coronary intervention
Drug-eluting stent 86.6%
Bare-metal stent 9.1%
PTCA 32.1%
Total stents used 325
Stents used per procedure 1.7 1.0
Total vessels treated 226
Vessels treated per procedure 1.2 0.5
Type C lesion treated 53.4%
Bifurcation lesion treated 17.1%
Vessel treated
Left main 4.9%
LAD 37.6%
Circumflex 30.1%
RCA 21.7%
Bivalirudin 85.9%
Unfractionated heparin 11.9%
Glycoprotein IIb/IIIa inhibitor 8.2%
Values are mean  SD or %.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass
index; CABG  coronary artery bypass grafting; CVD  cardiovascular disease; LAD  left anterior
escending coronary artery; MImyocardial infarction; PCI percutaneous coronary intervention;
TCA  percutaneous transluminal coronary angioplasty; RCA  right coronary artery.36.2  25.5%; p  0.34) were similar between those with
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Fibrinogen and Ischemic Risk During Elective PCI January 8, 2013:23–34and without a troponin I/T–defined PPMI. The prevalence
of high on-clopidogrel platelet reactivity defined as PRU
230 (48.0% vs. 45.2%; p  0.79), PRU 208 (52.0% vs.
1.6%; p  0.97), or PI 30% (60.0% vs. 45.2%; p  0.17)
was also similar between those with and without a troponin
I/T–defined PPMI.
Fibrinogen level, age, and platelet count were entered
together into a multiple variable regression model and both
fibrinogen (p  0.031) and age (p  0.035) remained
independently associated with troponin I/T–defined PPMI
(Table 3). Further testing did not show an interaction
between fibrinogen level and age. After on-treatment PRU
and PI were separately included into multiple variable
regression models with significant univariate factors (fibrin-
ogen level, age, and platelet count), only serum fibrinogen
level and age remained significantly associated with tro-
ponin I/T–defined PPMI. The aforementioned multiple
variable regression testing was repeated while including
other markers of systemic inflammation (CRP and white
blood cell count) (Table 3). When controlling for these
inflammatory markers, serum fibrinogen remained signifi-
cantly associated with troponin I/T–defined PPMI, whereas
age and platelet function measures did not.
CK-MB–defined PPMI. CK-MB measurements were
obtained in all subjects. The incidence of CK-MB–defined
PPMI was 5.8% (Table 4). There was no difference in
baseline characteristics, medical history, medication use, or
lipid profile between subject groups with or without a
Figure 1 ROC Curve Relating Level of Platelet Inhibition
With High On-Clopidogrel Platelet Reactivity
Platelet inhibition level 30% produced maximum sensitivity and specificity in
predicting high on-clopidogrel platelet reactivity defined as VerifyNow platelet
reactivity units (PRU) 230 (area under the curve [AUC]  0.950; 86.5% sen-
sitivity, 90.6% specificity; p  0.001). ROC  receiver-operating characteristic.PPMI. Among procedural characteristics suggesting higher PCI complexity, including treatment of type C or bifurca-
tion lesions, only the number of stents used per procedure
(2.36 0.92 vs. 1.68 1.02; p0.027) was associated with
occurrence of PPMI. On platelet function testing, baseline
PRU (312  32.7 vs. 328.2  57.8; p  0.38), on-
treatment PRU (224.7  96.4 vs. 210.8  91.4; p  0.62),
and PI (30.2 20.0% vs. 36.1 25.3%; p 0.45) were not
different between the 2 groups. The prevalence of high
on-clopidogrel platelet reactivity defined as PRU 230
(45.5% vs. 44.9%; p  1.00), PRU 208 (45.5% vs. 51.7%;
p  0.69), or PI 30% (63.6% vs. 45.5%; p  0.24) was
also similar between those with and without a CK-MB–
defined PPMI. However, subjects with PPMI had higher
fibrinogen levels (403.4  128.0 mg/dl vs. 313.5  104.6
mg/dl; p  0.007) without increase in CRP (CRP 0.5
g/dl; 36.4% vs. 25.7%; p  0.48). Serum fibrinogen level
alone remained significantly associated with CK-MB–
defined PPMI after significant univariate factors were in-
cluded together with either on-treatment PRU or PI within
multiple variable models. Furthermore, this relationship
remained significant when other markers of systemic in-
flammation (CRP, platelet count, and white blood cell
count) were included in the models.
ROC curve relating fibrinogen to PPMI. A ROC curve
showed a fibrinogen cutoff level of 345 mg/dl to have
optimal combined sensitivity and specificity for CK-MB–
defined PPMI (AUC: 0.700, p  0.026; 72.7% sensitivity,
64% specificity, positive predictive value 11.1%, negative
predictive value 97.4%) (Fig. 2A). The ROC curve analysis
did not yield a significant fibrinogen cutoff value to predict
troponin I/T–defined PPMI (AUC: 0.590; p  0.15).
However, those with a serum fibrinogen level 345 mg/dl
ad higher occurrence of PPMI by both troponin I/T 3
LN (20.9% vs. 9.7%; p 0.036) and CK-MB3 ULN
11.1% vs. 2.6%; p  0.023) (Fig. 3). Compared with
ichotomous markers of high on-treatment platelet reactiv-
ty, only elevated fibrinogen level 345 mg/dl was associ-
ted with increased risk of PPMI defined by either troponin
/T (odds ratio [OR]: 2.5; 95% confidence interval [CI]:
.04 to 5.77) (Fig. 4) or CK-MB (OR: 4.75; 95% CI: 1.21
o 18.5) (Fig. 5) definition.
ibrinogen and C-reactive protein. A secondary analysis
as performed to further evaluate the relationship between
brinogen level, systemic inflammation, and the risk of
PMI. In the absence of systemic inflammation (CRP0.5
g/dl, 73.7% of subjects), there was a higher incidence of
PMI among those with fibrinogen 345 mg/dl (troponin
/T–defined: 27.8% vs. 9.4%, p 0.007; CK-MB–defined:
6.2% vs. 1.0%, p  0.002) (Fig. 3). A ROC curve analysis
n subjects without elevated CRP also showed a fibrinogen
evel 345 mg/dl had greatest sensitivity and specificity for
redicting a CK-MB–defined PPMI (AUC: 0.821, p 
.004; sensitivity 85.7%, specificity 76.1%, positive predictive
alue 16.2%, and negative predictive value 99.0%) (Fig. 2B).
An interaction variable including elevated fibrinogen
345 mg/dl and CRP 0.5 mg/dl was entered together
27JACC Vol. 61, No. 1, 2013 Ang et al.
January 8, 2013:23–34 Fibrinogen and Ischemic Risk During Elective PCISubject Characteristics Stratified by Occurrence of aTroponin I/T (>3 ULN) Defined PPMITable 2 Subject Characteristics Stratifi d by Occurrence of aTroponin I/T (>3 ULN) Defined PPMI
No Troponin I/T–Defined PPMI
(n  155)
Troponin I/T–Defined PPMI
(n  25) p Value
Age, yrs 63.0 11.8 68.2 10.1 0.040
Male 72.3 84.0 0.215
BMI, kg/m2 28.5 5.6 27.1 4.3 0.221
Cardiovascular history
Past PCI 63.2 64.0 0.941
Past CABG 18.1 16.0 1.00
Past MI 29.6 33.3 0.711
Hypertension 89.0 96.0 0.475
Hyperlipidemia 90.3 80.0 0.163
Diabetes mellitus 44.5 60.0 0.150
Family history of CVD 30.7 32.0 0.898
Smoking history 15.8 20.0 0.568
Current PCI indication 0.949
Stable angina 56.1 52.0
Unstable accelerating angina 23.2 28.0
Other symptoms 11.0 12.0
Positive stress test 9.7 8.0
Medications
Aspirin 97.4 96.0 0.531
Statin 83.8 76.0 0.392
Beta-blocker 76.1 64.0 0.197
ACE inhibitor/ARB 61.3 56.0 0.615
Nitrates 28.4 28.0 0.968
Calcium channel blocker 24.5 20.0 0.623
Clopidogrel (75 mg daily 7 days) 85.2 80.0 0.552
Laboratory values
HDL, mg/dl 39.6 13.3 39.1 12.9 0.864
LDL, mg/dl 78.2 31.8 84.1 38.0 0.417
Triglycerides, mg/dl 118.5 73.2 137.6 71.9 0.237
WBC, cells  103/l 7.1 2.2 8.1 1.6 0.150
Hemoglobin, g/dl 12.9 1.6 13.3 1.7 0.320
Platelet count, cells  103/l 218.4 55.5 243.6 64.1 0.041
CRP 0.5 mg/dl 25.7 24.0 0.860
Fibrinogen, mg/dl 309.1 99.6 363.1 131.0 0.017
Percutaneous coronary intervention
Drug-eluting stent 85.1 91.7 0.536
Bare-metal stent 9.1 12.5 0.706
PTCA 28.6 33.3 0.633
Stents used per procedure 1.68 1.02 2.08 0.91 0.065
Vessels treated per procedure 1.23 0.48 1.35 0.57 0.304
Type C lesion treated 53.5 56.0 0.819
Bifurcation lesion treated 16.3 23.8 0.368
Bivalirudin 85.3 88.0 1.00
Unfractionated heparin 11.9 12.0 1.00
Glycoprotein IIb/IIIa inhibitor 8.1 12.0 0.456
Platelet function testing
Base PRU 362.7 58.1 324.1 60.7 0.837
Result PRU 209.8 92.1 226.0 84.5 0.411
Platelet inhibition 36.2 25.5 31.1 20.3 0.341
Result PRU 230 45.2 48.0 0.791
Result PRU 208 51.6 52.0 0.971
Values are mean  SD or %.
CRP  C-reactive protein; HDL  high-density lipoprotein; LDL  low-density lipoprotein; PPMI  periprocedural myocardial infarction; PRU 
P2Y12 reactivity units; WBC  white blood cell; other abbreviations as in Table 1.
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Fibrinogen and Ischemic Risk During Elective PCI January 8, 2013:23–34with fibrinogen and CRP level into multiple variable regres-
sion models to predict the occurrence of PPMI. This
interaction term remained predictive of CK-MB–defined
PPMI (OR: 11.6; 95% CI: 1.13 to 119) (whereas fibrinogen
or CRP level alone did not), but was not predictive of
troponin I/T–defined PPMI when either including or
excluding age and platelet count covariates. An interaction
variable between lower fibrinogen 345 mg/dl and CRP
0.5 mg/dl was also entered together with fibrinogen and
CRP level into a multiple variable regression model to
predict the absence of a CK-MB–defined PPMI, and was
found to be an independent negative predictor of CK-MB–
defined PPMI (OR: 0.086; 95% CI: 0.008 to 0.882)
(whereas fibrinogen or CRP level alone was not). In the
overall cohort, subjects with fibrinogen 345 mg/dl in the
absence of systemic inflammation (CRP 0.5 mg/dl) had
the highest incidence of CK-MB–defined PPMI (Fig. 6),
hereas those with fibrinogen345 mg/dl in the absence of
ystemic inflammation had the lowest incidence of CK-
B–defined PPMI (Fig. 7) compared with other variables
nown to affect the risk of PPMI.
iscussion
his study was undertaken to determine the roles of serum
Details of Multiple VariableR gre sion Analyses of FactorsAssociated With Trop nin I/T–Defined PPMI
Table 3
Details of Multiple Variable
Regression Analyses of Factors
Associated With Troponin I/T–Defined PPMI
Analysis
Including
Listed Factors
(p Value)
Analysis Including
Listed Factors, CRP,
and WBC Count
(p Value)*
Significant univariate factors alone
Fibrinogen level 0.031 0.020
Age 0.035 0.071
Platelet count 0.107 0.376
Significant univariate factors including
interaction variable
Fibrinogen level 0.040 0.018
Age 0.068 0.114
Fibrinogen and age 0.549 0.638
Significant univariate factors including
PRU
Fibrinogen level 0.036 0.022
Age 0.033 0.069
Platelet count 0.122 0.419
PRU 0.634 0.599
Significant univariate factors including PI
Fibrinogen level 0.043 0.024
Age 0.031 0.062
Platelet count 0.107 0.388
PI 0.544 0.403
Analyses were performed by including all listed factors together within the regressionmodel as well
as in combination with markers of systemic inflammation (CRP 0.5 mg/dl and WBC count).
Fibrinogen level remained significantly associated with troponin I/T–defined PPMI after testing
with other significant univariate factors, interaction testing, and controlling for markers of platelet
function as well as systemic inflammation. *CRP 0.5mg/dl and WBC count did not achieve
statistically significant p-values 0.05 in any of these analyses.
PI  platelet inhibition; other abbreviations as in Table 2.brinogen and residual platelet reactivity after clopidogrelpre-treatment on ischemic events after elective PCI. The
key findings of this study are: 1) elevated serum fibrinogen
(345 mg/dl) is independently associated with periproce-
dural myocardial infarction; 2) fibrinogen level is a signifi-
cant positive and negative predictor of PPMI in the absence
of baseline systemic inflammation (CRP0.5 mg/dl); 3) no
association between on-clopidogrel residual platelet reactiv-
ity and PPMI is observed; and 4) a PRU 230 as measured
with the VerifyNow assay corresponds to a platelet inhibi-
tion of 30.9%.
Using universal definitions of PPMI according to tro-
ponin I/T and CK-MB enzyme levels, elevated serum
fibrinogen level was associated with higher rate of PPMI
regardless of on-clopidogrel platelet reactivity using the
point-of-care VerifyNow P2Y12 assay. By ROC curve
analysis, fibrinogen level345 mg/dl significantly predicted
PPMI and identified individuals undergoing elective PCI
with nearly a 5-fold increased odds of experiencing a
CK-MB–defined PPMI. A secondary analysis demon-
strated that a fibrinogen level of 345 mg/dl was an even
stronger positive and negative predictor of PPMI among
those without baseline systemic inflammation. No relation-
ships between measures of platelet reactivity using the
VerifyNow P2Y12 assay and PPMI were detected in this
study, but the significance of these negative findings may be
limited due to inadequate study power. Measurement of
sensitive periprocedural ischemic markers of myocardial
injury (CK-MB and troponin I/T) within a controlled
environment, during which medication noncompliance was
not an issue, add to the reliability of these findings.
Furthermore, patients with acute myocardial infarction were
excluded to minimize confounding variables, and no pa-
tients had an angiographic etiology for a PPMI. These
findings are highly pertinent from both a mechanistic and
clinical standpoint.
Mechanistically, both serum fibrinogen and activated
platelets are key components of arterial thrombus formation
(22). Circulating platelets are activated by soluble platelet
agonists (such as ADP, epinephrine, thrombin, and colla-
gen) causing conformational shifts of glycoprotein IIb/IIIa
receptors and externalization of these receptors to the
platelet cell surface. Activated receptors then bind to circu-
lating fibrinogen and fibrin molecules, and facilitate platelet
crosslinking, thrombosis, and clot formation. Platelet acti-
vation also facilitates release of platelet alpha-granules,
containing additional fibrinogen and other coagulation fac-
tors, further promoting localized thrombus formation
(22,23). Due to the interplay between fibrinogen and
ADP-mediated platelet activation during thrombus forma-
tion, uncertainty exists regarding the independent effects of
these factors on adverse thrombotic and ischemic cardiac
events. However, the results of the current study suggest
that an elevated fibrinogen level 345 mg/dl is related to
significant platelet cross-linking and thrombus formation
independent of residual P2Y12 receptor-mediated platelet
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No CK-MB–Defined PPMI
(n  178)
CK-MB–Defined PPMI
(n  11) p Value
Age, yrs 63.7 11.7 65.7 10.1 0.568
Male 73.6 81.8 0.731
BMI, kg/m2 28.5 5.5 27.2 4.6 0.457
Cardiovascular history
Past PCI 62.9 63.6 1.00
Past CABG 18.5 9.1 0.692
Past MI 29.3 36.4 0.735
Hypertension 89.9 100 0.604
Hyperlipidemia 90.4 72.7 0.096
Diabetes mellitus 46.1 54.5 0.584
Family history of CVD 30.1 27.3 1.00
Smoking history 16.0 18.2 0.692
Current PCI indication 0.798
Stable angina 56.7 45.5
Unstable accelerating angina 23.0 36.4
Other symptoms 10.7 9.1
Positive stress test 9.6 9.1
Medications
Aspirin 97.2 100 1.00
Statin 84.2 72.7 0.394
Beta-blocker 74.7 63.6 0.480
ACE inhibitor/ARB 62.4 54.5 0.751
Nitrates 29.2 36.4 0.735
Calcium channel blocker 24.2 27.3 0.731
Clopidogrel (75 mg daily 7 days) 84.3 90.9 1.00
Laboratory values
HDL, mg/dl 39.8 13.4 41.3 13.2 0.721
LDL, mg/dl 78.0 31.0 90.5 51.8 0.219
Triglycerides, mg/dl 120.1 73.3 131.9 44.4 0.597
WBC, cells  103/l 7.1 2.0 8.3 1.8 0.051
Hemoglobin, g/dl 12.9 1.6 13.9 2.0 0.056
Platelet count, cells  103/l 220.2 56.2 237.5 63.1 0.328
CRP 0.5 mg/dl 25.7 36.4 0.484
Fibrinogen, mg/dl 313.5 104.6 403.4 128.0 0.007
Percutaneous coronary intervention
Drug-eluting stent 85.8 100 0.365
Bare-metal stent 9.1 9.1 1.00
PTCA 31.3 45.5 0.334
Stents used per procedure 1.68 0.99 2.36 0.92 0.027
Vessels treated per procedure 1.24 0.49 1.10 0.32 0.202
Type C lesion treated 52.8 63.6 0.485
Bifurcation lesion treated 16.9 20.0 0.681
Bivalirudin 86.1 81.8 0.656
Unfractionated heparin 11.5 18.2 0.623
Glycoprotein IIb/IIIa inhibitor 7.6 18.2 0.224
Platelet function testing
Base PRU 328.2 57.8 312.5 32.7 0.383
Result PRU 210.8 91.4 224.7 96.4 0.624
Platelet inhibition, % 36.1 25.3 30.2 20.0 0.446
Result PRU 230 44.9 45.5 1.00
Result PRU 208 51.7 45.5 0.688Values are mean  SD or %.
CK-MB  creatine kinase-myocardial band; other abbreviations as in Tables 1 and 2.
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general inflammation.
Clinically, both elevated serum fibrinogen and high
on-treatment platelet reactivity signify increased risk of
adverse ischemic cardiovascular events. Large epidemiolog-
ical studies have shown fibrinogen to be an independent
long-term risk factor for primary MACE, including death,
nonfatal myocardial infarction, and stroke (12–15). Other
smaller studies with shorter follow-up periods have also
shown fibrinogen to be an independent risk factor for repeat
MACE in those with existing coronary artery disease
(6–11,24). Similarly, the GRAVITAS trial and a number of
smaller studies have shown that higher platelet reactivity
with clopidogrel therapy is independently associated with an
increased risk of adverse thrombotic and ischemic cardio-
vascular events following PCI (20,21). However, the posi-
tive predictive value of platelet reactivity measures for such
events is low, and there is limited consensus on the
definition of suboptimal platelet inhibition (4,5,20,21,25).
Our group (17,26) and others (6,27) have previously
shown an association between elevated fibrinogen level and
lower platelet reactivity during antiplatelet therapy. Using
the VerifyNow IIb/IIIa assay, we have shown an association
between fibrinogen level 375 mg/dl and inadequate inhi-
bition of platelet aggregation during PCI despite single- or
double-bolus administration of the potent glycoprotein
IIb/IIIa inhibitor eptifibatide (26). In another study, using
the VerifyNow P2Y12 assay, we demonstrated that fibrin-
ogen level 375 mg/dl was associated with higher residual
platelet reactivity following clopidogrel pre-treatment be-
Figure 2 ROC Curve Relating Fibrinogen Level With and Withou
(A) ROC curve relating fibrinogen level to PPMI. Fibrinogen level 345 mg/dl prod
PPMI (AUC: 0.700; 72.7% sensitivity; 64% specificity; 11.1% positive predictive v
gen level without systemic inflammation to PPMI. Fibrinogen level 345 mg/dl
sensitivity and specificity in predicting a CK-MB (3 ULN) defined PPMI (AUC
negative predictive value 99.0%; p  0.004). AUC  area under the curve; CK
tion; ULN  upper limit of normal.fore PCI (17). Althoff et al. (6) used multiple electrodeaggregometry (Multiplate analyzer, Dynabyte, Munich,
Germany) and identified both serum fibrinogen and recent
myocardial infarction as independent risk factors for subse-
quent elevated platelet reactivity during dual-antiplatelet
therapy with aspirin and clopidogrel. Bernlochner et al. (27)
used the Multiplate analyzer to demonstrate a relationship
between a fibrinogen level 350 mg/dl and higher platelet
aggregation following PCI and dual antiplatelet treatment
using aspirin and clopidogrel. Recognizing the association
between increased fibrinogen and platelet reactivity, the
current study was designed to prospectively evaluate the
roles of baseline serum fibrinogen and platelet reactivity
following dual antiplatelet therapy (aspirin and clopidogrel)
in predicting a short-term, adverse ischemic cardiac event
following elective PCI.
In this study, a fibrinogen level 345 mg/dl had the
greatest sensitivity and specificity after ROC curve analysis
for predicting CK-MB–defined PPMI, and this level also
remained significantly associated with troponin I/T–
defined PPMI. Other groups, including Arnau Vives et al.
(7), Toss et al. (8), and Kaski et al. (24), studied
higher-risk individuals with non–ST-segment elevation
acute coronary syndromes and reported fibrinogen cutoff
levels of 375 mg/dl (upper tertile/ROC curve), 400 mg/dl
(upper tertile), and 447 mg/dl (ROC curve) to be
predictive of repeat occurrence of MACE. The ROC
curve analyses from studies by Toss et al. (8), Kaski et al.
(24), and the current study show similar results, with
AUC ranges of 0.70 to 0.73 (sensitivity 60% to 73%,
specificity 64% to 70%) and fibrinogen cutoffs possessing
temic Inflammation to PPMI
he greatest sensitivity and specificity in predicting a CK-MB (3 ULN) defined
97.4% negative predictive value; p  0.026). (B) ROC curve relating fibrino-
absence of systemic inflammation (CRP 0.5 mg/dl) produced the greatest
1; sensitivity 85.7%; specificity 76.1%; positive predictive value 16.2%; and
creatine kinase-myocardial band; PPMI  periprocedural myocardial infarc-t Sys
uced t
alue;
in the
: 0.82
-MB low positive predictive values (6.2% to 14.9%) and high
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tion observed between our cutoff value of 345 mg/dl and
the others is likely attributed to differences in study
populations (lower-risk elective PCI subjects in our
Figure 3 Fibrinogen Level and PPMI in Elective PCI
The incidence of both troponin I/T (3 ULN) defined PPMI (20.9% vs. 9.7%; p 
(B) was greater in those with elevated fibrinogen level 345 mg/dl. In subjects w
an even higher incidence of PPMI was observed (troponin I/T–defined 27.8% vs. 9
C-reactive protein; PCI  percutaneous coronary intervention; other abbreviations
Figure 4
Risk of PPMI (Troponin I/T >3 ULN)
With Elevated Fibrinogen and
High On-Clopidogrel Platelet Reactivity
Elevated fibrinogen level (345 mg/dl) is associated with an increased risk of
a troponin I/T–defined PPMI (odds ratio: 2.5; 95% confidence interval (CI):
1.04 to 5.77), whereas no such risk is observed with on-clopidogrel treatment
platelet reactivity. PI  platelet inhibition; other abbreviations as in Figure 2.study) and outcomes measured. The overall predictive
ability of these cutoffs suggests that depressed fibrinogen
level accurately signifies a lower risk of secondary throm-
botic/ischemic cardiac events, whereas elevated fibrino-
) (A) and CK-MB (3 ULN) defined PPMI (11.1% vs. 2.6%; p  0.023)
vated fibrinogen (345 mg/dl) without systemic inflammation (CRP 0.5 mg/dl),
 0.007 [A] and CK-MB–defined 16.2% vs. 1.0%; p  0.002 [B]). CRP 
igure 1.
Figure 5
Risk of PPMI (CK-MB >3 ULN)
With Elevated Fibrinogen and
High On-Clopidogrel Platelet Reactivity
Elevated fibrinogen level (345 mg/dl) is associated with a much greater risk
of a PPMI (odds ratio: 4.75; 95% CI: 1.21 to 18.5), whereas no increased risk
is observed with higher on-clopidogrel platelet reactivity. Abbreviations as in
Figures 2, 3, and 4.0.036
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note, we demonstrated an incrementally increased AUC
(0.821) and predictive values (sensitivity 85.7%, specific-
ity 76.1%, positive predictive value 16.2%, and negative
predictive value 99.0%) after performing ROC curve
analysis among subjects with CRP 0.5 mg/dl, suggest-
ing an improved positive and negative predictor role for
fibrinogen in the absence of systemic inflammation.
Platelet function testing after clopidogrel pre-treatment is
similarly limited in its ability to positively predict secondary
ischemic cardiac events. The current study did not show an
association between measures of platelet reactivity and PPMI,
though it may have been inadequately powered to evaluate
these relationships. This finding is inconsistent with the results
of several smaller studies that used the VerifyNow P2Y12 assay
to predict adverse thrombotic cardiac outcomes following PCI
for both acute coronary syndromes (28,29) and elective indi-
cations (30,31). The ROC curve analyses used in each of these
studies resulted in PRU cutoffs of 235, 236, and 240 to predict
adverse cardiac events. These analyses as a group produced
ranges of AUC (0.62 to 0.71), sensitivity (60% to 81%),
specificity (53% to 70%), positive predictive value (12% to
81%), and negative predictive value (91% to 99%) that indicate,
similar to serum fibrinogen concentration, lower VerifyNow
PRU predicts superior clinical outcomes, but higher PRU
alone does not reliably predict adverse ischemic events.
In the current study, we also report a strong association
Figure 6 Incidence of PPMI in the Presence of Factors Associa
Subjects with baseline fibrinogen level 345 mg/dl had a higher incidence of both
and troponin I/T–defined PPMI (†controlled for age, platelet count, platelet reactiv
elevated baseline fibrinogen level in the absence of systemic inflammation (CRP 
variable interaction testing (‡controlled for fibrinogen and CRP), but higher inciden
*†‡Multiple variable regression p value 0.05; §univariate p value 0.05. Abbrebetween VerifyNow PRU 230 and PI 30.9%. This cfinding can be helpful in interpreting the results of studies
identifying clinically significant VerifyNow PRU cutoffs and
those using traditional LTA to identify clinically significant
levels of PI. A number of previous studies have used LTA
with a 10 mol/l ADP agonist and ROC curve analyses to
dentify PI of 30% as a significant cutoff, below which
ndividuals are at greater risk of adverse cardiac events
32–35). In addition, the current study shows that although
5% of subjects have high on-clopidogrel platelet reactivity
efined as PRU 230, a slightly larger percentage (53%) of
ubjects attained PI 30%, and a small portion of these
ndividuals would be considered as appropriate clopidogrel
esponders using a PRU-based definition alone. Most impor-
antly, it might not be appropriate to define cutoff values that
re based on a single assay or level of platelet reactivity, but
onsideration should be given to reporting outcomes in future
tudies based on a range of inhibition of platelet reactivity as it
s more generalizable and better understood by the majority of
linicians.
tudy limitations. The current study was not designed to
e-examine the relationship between fibrinogen and platelet
eactivity, but rather to assess for interactions between these
ariables in predicting a short-term adverse cardiac event.
he results of these analyses showed a relationship between
brinogen and PPMI independent of VerifyNow P2Y12
latelet reactivity measures. A relationship between platelet
eactivity and PPMI was not found in this study, but
ith an Increased Risk of Ischemic Myocardial Injury During PCI
B–defined PPMI (*controlled for platelet reactivity and inflammatory markers)
d inflammatory markers) supported by multiple variable testing. Subjects with an
g/dl) had an even higher incidence of CK-MB–defined PPMI based on multiple
roponin I/T–defined PPMI was only supported by univariate analysis (§).
s as in Figures 2 and 3.ted W
CK-M
ity, an
0.5 m
ce of t
viationonclusions drawn from this result may be limited due to
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VerifyNow P2Y12 assay methodology, and other tests of
platelet reactivity may yield different results. The findings of
this study do not provide insight into whether the relation-
ship between high platelet reactivity and ischemic cardio-
vascular events demonstrated in previous studies is a direct
one or mediated through the effect of serum fibrinogen.
Future studies evaluating platelet reactivity and adverse
cardiovascular events should include simultaneously mea-
sured serum fibrinogen to clarify this relationship. Further-
more, though relationships between fibrinogen, low CRP,
and PPMI were observed in a secondary analysis, limited
conclusions should be drawn regarding lack of similar
relationships in those with higher CRP. The significance of
the reported fibrinogen cutoff may vary when related to
different populations or outcome measurements.
Conclusions
In elective PCI patients, elevated serum fibrinogen is
independently associated with PPMI regardless of on-
treatment platelet reactivity or platelet inhibition using the
VerifyNow P2Y12 assay. Fibrinogen level 345 mg/dl
signifies an increased risk of a PPMI, especially in the
absence of systemic inflammation (CRP 0.5 mg/dl),
whereas no relationship between high platelet reactivity and
PPMI is present in this elective PCI study population.
Future studies relating platelet reactivity and adverse cardiac
Figure 7 Incidence of PPMI in the Absence of Factors Associa
Subjects with baseline fibrinogen level 345 mg/dl had lower incidence of both C
troponin I/T–defined PPMI (†controlled for age, platelet count, platelet reactivity, a
line fibrinogen level 345 mg/dl and absence of systemic inflammation (CRP  0
interaction testing (‡controlled for fibrinogen and CRP), but lower incidence of trop
able regression p value 0.05; §univariate p value 0.05. Abbreviations as in Figevents should measure baseline fibrinogen to clarify whethersuch a relationship is a direct one or mediated through
independent fibrinogen effects.
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